Emerging Markets Earnings Roundup: AstraZeneca And Roche (Part 4)
This article was originally published in PharmAsia News
Executive Summary
Although AstraZeneca achieved 17% growth in China for 2012, there is room for improvement, CEO Pascal Soriot told investors. Meanwhile, Soriot’s old company Roche seems to be discussing emerging markets less on its quarterly calls since he left, but nevertheless ramps up sales for key products Avastin and Herceptin.
You may also be interested in...
On Soriot’s List For AstraZeneca: Building A Decision-Making Culture
AstraZeneca investors will have to wait two more months to hear details of CEO Pascal Soriot’s plans for re-energizing the struggling big pharma. But the new chief did discuss several near-term objectives for the company and what he has pinpointed as being some of the operational problems, based on discussion with hundreds of employees, during a year-end financial call Jan. 31.
Roche’s Oncology Output Could Lead To Reimbursement Problems Down The Line
Roche posted solid 2012 results and development of new cancer drugs continues apace, forecasting further sales and profit gains in 2013 and beyond – as long as government insurers can handle the abundance.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.